



ANNUAL REPORT 2016



SAMUEL WAXMAN CANCER
RESEARCH FOUNDATION

ANNUAL REPORT

2016

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells. Our mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer. This research is the basis for developing minimally toxic treatments for patients.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, The Foundation has awarded approximately \$90 million to support the work of more than 200 researchers across the globe.

40
YEARS OF
COLLABORATION



SAMUEL WAXMAN CANCER
RESEARCH FOUNDATION

OUR VISION

Dear Friend,

The SWCRF's 40th anniversary last year presented a good opportunity to take stock of the major changes in how we treat cancer patients today. Progress can be best described as incremental, a stepwise translation of research to clinical trials with sometime dramatic clinical impact. Cancer treatment has evolved into a more personalized selection of treatment options based on understanding the nature of the cancer using technology that has evolved during the past ten years. Although traditional chemotherapy remains the mainstay of treatment, it is no longer necessary to apply the concept of treating fire with fire to cancer therapy. During the last ten years more anti-cancer drugs have been approved by the FDA than in the past 50 years. These drugs are less toxic, based on basic research described many years ago, and are beginning to replace traditional chemotherapy. The death rates for most cancers have been considerably decreased, however, at great cost and uncertainty remains. It is amazing to see patients who have extraordinary responses to these new treatments such as former president Jimmy Carter, who reportedly had melanoma metastasis in the brain and responded to a novel treatment.

The SWCRF can be proud that for 40 years we have taken this approach to cancer therapy. As described in this annual report, the differentiation therapy of acute promyelocytic leukemia (APL), which resulted in a 95 percent cure rate, is the antecedent to today's new approach to treatment. With this type of therapy, there is minimal damage to normal cells so the potential for development of a new cancer is markedly diminished. This requires collaboration to leverage the talents of many investigators to target a common goal of creating scientifically based, minimally toxic therapies. The international collaborations encouraged by the SWCRF have initiated clinical trials by SWCRF investigators working in Tel Aviv, Chicago, Houston and Boston, to name but a few. This offers hope to all that cancer can be a manageable disease without losing quality of life due to the toxicity of most treatments.

Cancer incidence continues to rise around the world although mortality rates are decreasing. This is due to the growing incidence of cancer in our aging population which is predicted to increase dramatically around the world. The SWCRF is taking a leadership role in bringing together scientists working in aging and cancer to confront this problem. We have initiated collaborations with the National Cancer Institute, the National Institute on Aging and other Foundations to build a consortium with the capacity to give us insight on the management of this growing epidemic. Today, the SWCRF Institute Without Walls is in a growth phase anchored by our new Executive Director, William Sullivan, a strong Foundation staff, a dedicated Board of Directors and our devoted donors. Together we will continue to play an important role in making cancer a curable disease.

Remember, we can't do this without you.

Sincerely,



Michael Nierenberg
Chairman



Samuel Waxman, M.D.
Founder and CEO



Spencer Waxman
President



Michael Nierenberg



Samuel Waxman, M.D.



Spencer Waxman

2016

YEAR IN REVIEW

40
YEARS OF
COLLABORATION



SAMUEL WAXMAN CANCER
RESEARCH FOUNDATION

MAY 18



On May 18, philanthropist Andrea Stark hosted the third annual Collaborating for a Cure Luncheon to benefit SWCRF. The fundraiser featured a presentation of the Fall 2016 Oscar de la Renta collection.

JULY 14



The 34th annual SWCRF golf outing and dinner honored professional golf instructor Jim McLean at The Creek on July 14 and raised \$200,000 for cancer research.

OCTOBER 6



St. John returned to the Pay It Forward campaign for a second year by staging a reception and informal fashion presentation at its Fifth Avenue boutique on October 6.

JULY 8



SWCRF supporters, Hamptons Happening committee members and friends joined Dr. Waxman in ringing the opening bell at NASDAQ to celebrate the SWCRF's 40th Anniversary on July 8.

SEPTEMBER 28



The SoHo concept store of Lafayette 148 New York hosted a shopping night in support of SWCRF's Pay It Forward program on September 28. The event was hosted by Dan Lawson, stylist for the CBS series "The Good Wife."

OCTOBER 20



The Angelo David salon supported SWCRF breast cancer research on October 20 with the Second Annual Blow Out Breast Cancer, a one-day marathon of \$25 blow outs, silent auctions and hair brush sales. Supporters included Tabooze and Baked in Color cookies.

MAY 2



SWCRF donors, board members, and friends raised a glass to Dr. Samuel Waxman and the Samuel Waxman Cancer Research Foundation at the SWCRF 40th Anniversary Awards Celebration that recognized major supporters at Mount Sinai Medical Center on May 2. Dr. Tim Ley received the David T. Workman Award.

JULY 9



The twelfth annual A Hamptons Happening raised \$300,000 for research on July 9. The honorees were Deirdre Quinn, Sandra Lee and Jayma Cardoso.

OCT 1 - OCT 31



SWCRF Chairman's Council member Tadashi Shoji returned to the annual Pay It Forward fundraiser for a third year by designing a limited edition scarf to benefit SWCRF breast cancer research throughout October.

NOVEMBER 10



The 19th annual Collaborating for a Cure Gala introduced the SWCRF Vince Camuto Memorial Cancer Research Program and raised \$2.5 million on November 10. The night featured a performance by Roger Daltrey of The Who with a surprise appearance by Willie Nile.

SWCRF AGING & CANCER INITIATIVE PROGRESSES

The Samuel Waxman Cancer Research Foundation (SWCRF) has made great strides in the development of its new Aging and Cancer research initiative. The program is the brainchild of SWCRF Founder and CEO Samuel Waxman, M.D., who identified an unmet need for research on the causal roles of genetic and environmental factors in the rising incidence of cancer as people age. Dr. Waxman appeared on the business news cable program Varney & Co. on June 7 to discuss this trend.


Cancer is a disease of aging and as people are living longer, global populations are projected to increase dramatically. The U.S. Census Bureau estimates that the population of people over 65 will reach 83.7 million in 2050, almost double its 2012 population of 43.1 million. As this population booms, so will the burden of cancer. According to the National Cancer Institute (NCI), cancer incidence increases dramatically after age 40 and the median age of people diagnosed with cancer in the United States is 65. Americans diagnosed with the most prevalent cancer types are, on average, over the age of 50. Despite these alarming statistics, research that focuses on the connections between aging and cancer is severely underfunded.

To address this growing health threat, the SWCRF is spearheading The Partnership for Aging & Cancer Research, a breakthrough collaboration among leading research and funding organizations to build a multiyear funding program that will pool the expertise of leading scientists in cancer and aging. The SWCRF has reached an agreement with the NCI in which the NCI will contribute three times the amount committed by the SWCRF. The SWCRF has also approached the American Federation for Aging Research (AFAR) and the National Institute on Aging (NIA) to join the Partnership, which aims to launch with a \$3 million budget to fund seven collaborating research teams over two years beginning in 2018. This is a novel synergistic collaboration between public foundations, philanthropists and government agencies: a "Moonshot" initiative.

"The growing incidence of cancer as people age is not a threat relegated to older people," says Dr. Waxman. "Our program targets the genetic damage that builds up over time throughout a person's life so it benefits children and adults of all ages. As our children are expected to live longer lives, their risk of getting cancer will be greater than ours."

Inspired by discussions among 15 leading cancer and aging researchers who participated in the SWCRF Aging & Cancer Workshop last year, research by this program's grantees would address how lifespan affects cancer development and how scientists can use their deepening knowledge of aging to enhance prevention or treatment of cancer. The initiative's long-term goal is to build a \$20 million funding program.

THE INCIDENCE OF MOST HUMAN CANCERS INCREASES WITH AGE



Source: National Cancer Institute

The Samuel Waxman Cancer Research Foundation appoints William T. Sullivan Executive Director



The Samuel Waxman Cancer Research Foundation (SWCRF) has appointed William T. Sullivan to the position of Executive Director. An accomplished leader with a track record of dramatically improving the efficiency and fundraising of high-profile nonprofit organizations, Mr. Sullivan brings more than 30 years of experience to his new post.

"The Board of Directors of the Samuel Waxman Cancer Research Foundation and I are delighted to welcome William Sullivan to our organization as Executive Director," said Samuel Waxman, M.D.,

founder and CEO of the Samuel Waxman Cancer Research Foundation. "His expertise in improving organizational infrastructure and maximizing fundraising in the nonprofit sector will greatly advance our mission to fund innovative epigenetic research to eradicate cancer."

"I have always admired the work of the Samuel Waxman Cancer Research Foundation and its excellent reputation," said William T. Sullivan. "It will be my honor to work with Dr. Waxman, the Board, the staff, and the Foundation's donors to further the important work of this noble organization."

Mr. Sullivan is a multifaceted strategic leader well regarded for his long tenures at Ronald McDonald House New York and the Greater New York Councils, Boy Scouts of America. He served as President and Chief Executive Officer of Ronald McDonald House New York for ten years during which the charity's annual operating budget tripled to \$20 million and net assets grew to \$122 million. Under Mr. Sullivan's leadership, the organization's volunteer leadership grew from 200 to over 850 active volunteers. Prior to his time at Ronald McDonald House, he had a 20-year tenure at the Greater New York Councils, Boy Scouts of America, rising through the ranks to the position of Chief Operating Officer. Most recently, Mr. Sullivan served as Director of Campaign Fundraising for New York City mayoral candidate Paul J. Massey, Jr.


OUR IMPACT

PROOF OF PRINCIPLE

Our philosophy of reprogramming cancer cells to function normally through differentiation led to a breakthrough treatment for acute promyelocytic leukemia (APL). The treatment, developed through collaboration between SWCRF founder and CEO Samuel Waxman, M.D., and researchers from the Shanghai Institute of Hematology, dramatically improved the survival rate of APL, which had a 100 percent fatality rate, to 95 percent, saving countless lives. It remains the course of treatment for the disease.

OUR INVESTMENT IN RESEARCH

- We support leading researchers in a wide range of cancer categories.
- Since 1976, we've awarded \$90 million to over 200 researchers worldwide.
- In the past ten years alone we've invested more than \$23 million in cancer research.



OUR FUNDED SITES

- | | | | | | | |
|--|--|---|---|---|----------------------------|----------------------------------|
| Baylor College of Medicine | Dana Farber Cancer Institute | Dartmouth Medical School | Icahn School of Medicine at Mount Sinai | Jewish General Hospital/McGill University | Johns Hopkins University | Massachusetts General Hospital |
| MD Anderson Cancer Center | Memorial Sloan-Kettering Cancer Center | Northwestern University | NYU Langone Medical Center | Ontario Cancer Institute | Salk Institute | Shanghai Institute of Hematology |
| Stanford University School of Medicine | Tel Aviv University | University of California, San Francisco | University of Florida Health | University of North Carolina, Chapel Hill | University of Pennsylvania | University of Toronto |
| University of Utah | Weill Cornell Medical Center | Whitehead Institute for Biomedical Research | | | | |

CLINICAL TRIALS

Our funded research has led to new clinical trials currently in process at several research institutes for potential treatments for liver, ovarian, breast and pediatric cancer.

THE POWER OF SWCRF COLLABORATION

Donations to the Samuel Waxman Cancer Research Foundation fuel progress and hope in science's quest for cancer cures.



Dr. Samuel Waxman and the SWCRF Scientific Advisory Board (front row) surrounded by the collaborating scientists of the SWCRF Institute Without Walls

Collaboration is the bedrock of scientific progress.

To this end, the Samuel Waxman Cancer Research Foundation (SWCRF) is a pioneer in fostering partnerships among scientists that facilitate information exchange to advance scientific progress. Their common focus on epigenetics enables findings in one cancer category to benefit investigation in others. This community of collaborators working throughout the world has produced many FDA-approved drugs and boasts several concurrent clinical trials for potential new therapies in a range of cancers.

Researchers who form the SWCRF's brain trust, the Institute Without Walls, laud the pivotal role the SWCRF's philosophy of cross-institutional collaboration has played in their work and that of their colleagues.



Hua Yu, Ph.D.

Hua Yu, Ph.D., co-leader of the Immuno-Oncology Program at the Comprehensive Cancer Center at City Of Hope, is a member of the SWCRF Scientific Advisory Board (SAB). The SAB vets applications for grants and evaluates the progress of currently funded researchers.

Dr. Yu, whose affiliation with the SWCRF began eight years ago, regards the Waxman Foundation's annual Scientific Review and Symposium a catalyst for scientific innovation. She has witnessed firsthand the impact of scientific collaboration in making discoveries and creating new approaches to treating

cancer. "Collaboration with other scientists, especially those I've met over the years through my involvement with the Samuel Waxman Cancer Research Foundation, is a critical part of my work and achieving our shared goal," says Dr. Yu. "The interchange of information during the SWCRF review benefits all researchers and is making a true difference for cancer patients."

Dr. Yu sees great potential in the SWCRF's new Partnership for Aging and Cancer Research to make impact in the ability to reach intracellular targets underlying age-related cancer by antibodies. In her own research, she is excited about her team's establishment of a novel platform to deliver antibodies, peptides into cells and/or nucleus to target molecules that are crucial, yet non-druggable for the treatment of cancer and other devastating diseases.



Kevan Shokat, Ph.D.

Kevan M. Shokat, Ph.D., is another eight-year veteran of the SWCRF Institute Without Walls. Dr. Shokat, Professor and Vice-Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco (UCSF), collaborates with SWCRF researchers on brain cancer. His work involves efforts to develop small molecule inhibitors of driver oncogenes that cause numerous cancers, including glioblastoma, breast cancer, and lung cancer.

Dr. Shokat and his collaborators seek to develop drug candidates that could test their hypotheses about which targets would lead to new drugs. He credits the SWCRF's annual review with adding measurable value to his work through collaboration with fellow grantees, including his colleague at UCSF, William Weiss, M.D., Ph.D.

"I have enjoyed the focused two-day meetings where we heard the latest unpublished results from other Waxman grant recipients," says Dr. Shokat. "This fertilized new ideas and collaborations and my close work with William Weiss, funded in part by the SWCRF, has been the most valuable collaboration in my career. I also began a collaboration with a number of other SWCRF awardees, such as Dr. Jeff Settleman, who was at Harvard at that time."

Dr. Shokat's work has developed Rapa-Link, an inhibitor of a mutation present in brain cancer. He and Dr. Weiss have shown that this molecule is a breakthrough in treating glioblastoma. The collaborators have licensed the compound to a start-up company in the hopes of introducing it at the clinical level.



Ross Levine, M.D.

At Memorial Sloan Kettering Cancer Center, Ross Levine, M.D., is a physician-scientist who investigates the genetic basis of malignancies in the formation of blood. He is a relative newcomer to the Institute Without Walls, having joined three years ago, and has found it to be an amazing experience enabling him to hear about the work of his fellow grantees and to receive their feedback on his research.

"It has been a tremendous experience, to be able to work with others in such an open and collaborative environment," he notes.

"Our studies have focused on mutations in epigenetic proteins, which occur as precursor mutations, in the normal aging population, and in acute leukemias," says Dr. Levine. "We have used support from SWCRF donors to uncover how these mutations contribute to aberrant blood cell development and to uncover approaches to target these mutations, including in patients before they develop cancer."

Dr. Levine's work in blood malignancies complements the SWCRF's Aging & Cancer Research initiative, which aims to uncover the causal genetic and environmental factors that cause growing cancer mortality among people as they age.

His team's recent work showing that pre-leukemic mutations can occur in patients with solid tumors and affect outcome opens up new questions on how, particularly in the aging setting, cancers can interact with blood cells and how this might promote cancer and cause resistance to therapies.

"The power of bringing together the world's most brilliant cancer researchers at the SWCRF annual review cannot be underestimated," says Samuel Waxman, M.D., founder & CEO of the Samuel Waxman Cancer Research Foundation. "Our two days of presentations provide an exchange unmatched in the world of science and we thank our donors, whose gifts support a vehicle that fosters inspiration, partnership and innovation that's changing the cancer research landscape."

FIGHTING LIVER CANCER WHERE IT LIVES

SWCRF grantee Josep M. Llovet, M.D., leads research and clinical trials at the frontline of a growing cancer threat.



Josep M. Llovet, M.D.

Liver cancer is on the rise in the United States. Although a recent report from the American Cancer Society indicated that cancer-related death rates have decreased 25 percent over the past 25 years, liver cancer continues to grow, increasing by about three percent annually among women and by four percent in men. This growth is attributed to the growing presence of hepatitis C as well as alcohol consumption. The National Cancer Institute (NCI) projected that in 2016 there would be 39,230 new cases of liver and intrahepatic bile duct cancer and more than 27,000 people would die of the disease.

The Samuel Waxman Cancer Research Foundation's (SWCRF) funded liver cancer research program at the Tisch Cancer Institute at Mount Sinai Medical Center operates at an epicenter of the cancer's threat - New York City's Harlem and East Harlem neighborhoods, which have among the highest incidences of liver cancer in the U.S. due to a high prevalence of chronic viral hepatitis, fatty liver and obesity linked to poor dietary habits.

Led by SWCRF grantee Josep M. Llovet, M.D., and Scott Friedman, M.D., the program has generated seminal studies elucidating the development and treatment of hepatocellular carcinoma (HCC) and intrahepatic

cholangiocarcinoma (iCCA), two forms of liver cancer with rapidly rising incidence. The SWCRF has donated about \$1.3 million to the Mount Sinai liver cancer program since its founding in 2003. It is the only program focused on liver cancer among 69 cancer centers and 770 programs supported by the NCI and leads the United States in liver cancer trial enrollments.

"The support of the Samuel Waxman Cancer Research Foundation and Dr. Samuel Waxman has been pivotal to the inroads our program has made over the past 14 years," said Dr. Llovet. "We are a leader in initiating clinical trials for new liver cancer therapies and we owe much of our progress to Dr. Waxman's contributions as a researcher and the generous donations of SWCRF supporters."

As Director of the program, Dr. Llovet has collaborated frequently with SWCRF Founder and CEO Samuel Waxman, MD, and is a central figure in the center's many clinical trials and international collaborations. He led a pivotal trial to test the multikinase inhibitor sorafenib in HCC and the treatment's positive results heralded a breakthrough in the management of patients at advanced stages of the disease. This international study was recognized as the first abstract in the plenary session at the annual meeting of the American Society of Clinical Oncology in 2007, highlighted as one of the six most relevant oncology advances of that year in the scientific journal *Clinical Oncology*, and was published in the *New England Journal of Medicine*.

Dr. Llovet, a past president of the International Liver Cancer Association (ILCA) and Chair of the European guidelines of management of HCC, has served as principal investigator on several trials that positioned Mount Sinai as the leader in global recruitment of liver cancer patients in the U.S., including two sorafenib trials sponsored by Bayer Pharmaceuticals. The program has seven active studies in process for HCC with patient recruitment during the last four years exceeding 80 participants and has recruited over 200 patients for other research studies.

REFLECTIONS ON 30 YEARS OF THE SHANGHAI INSTITUTE OF HEMATOLOGY

One of China's preeminent cancer researchers, Professor Zhen-Yi Wang, looks back on three decades of collaboration between the SIH and the Samuel Waxman Cancer Research Foundation.



Prof. Zhen-Yi Wang, Dr. Samuel Waxman And Prof. Zhu Chen

What inspired you to become a hematologist and scientist and how was it possible to navigate through the challenges during and following the Cultural Revolution?

I decided to be a doctor because I wanted to save people's lives. Throughout my career, I have benefited a lot from my patients who pushed me to keep thinking and exploring. During the Cultural Revolution, I never gave up on my studies, educating myself by reading the literatures and books edited by hematologists of the US and Europe.

How did you meet Dr. Samuel Waxman?

In 1983, I attended a conference in New York City and intended to visit some academic institutions while there. A colleague of mine, Dr. Guoying Shao, was working at Dr. Samuel Waxman's lab at Mount Sinai as a visiting scientist at the time. He introduced me to Dr. Waxman and I had the opportunity to visit his lab, thus beginning our long friendship and collaborations over 30 years.

Please describe your collaboration with Dr. Waxman on the landmark differentiation of APL with ATRA.

We began our collaboration with Dr. Waxman in the early 1980s. In 1988, our first paper reporting the dramatic effect of ATRA in treating APL

was published in the journal BLOOD through the pivotal support of Dr. Waxman. In 1991, Dr. Waxman invited me to give a talk at the Mount Sinai School of Medicine to report on the progress of differentiation therapy of APL with ATRA. In 1992, I received a distinction from the SWCRF for my work on differentiation therapy. That same year, the Samuel Waxman Cancer Research Foundation Laboratory was established at the Shanghai Second Medical University (SSMU), presently Shanghai Jiao Tong University, to further advance the study of differentiation therapy, creating the first joint lab of international collaboration at SSMU. In 1997, the collaboration was further enhanced through the establishment of the SSMU and SWCRF Joint Clinical and Experimental Research Center for Cancer Differentiation Therapy at Rui-Jin Hospital. Dr. Waxman also initiated the series of international symposiums on differentiation therapy in Shanghai which have promoted the clinical and basic research of differentiation therapy. The wonderful collaboration between the East and the West has dramatically changed the clinical outcome of a malignant disease and saved the lives of thousands of patients.

How has the Shanghai Institute of Hematology (SIH) evolved during the past 30 years?

Benefiting from the rapid pace of scientific development in China, and also owing to the support from our colleagues and friends at home and abroad, the SIH has developed rapidly from a small institute to an influential academic institution in China and in the world. The Institute

1982

Samuel Waxman Cancer Research Foundation (SWCRF) begins its collaboration with Prof. Zhen Yi Wang of the Shanghai Second Medical University, a relationship that preceded the founding of the Shanghai Institute of Hematology (SIH) in 1987.



1996

Samuel Waxman, M.D., receives an honorary Professorship from the Shanghai Second Medical University and the Magnolia Award from the Shanghai Municipal government for contributions to the treatment of leukemia.

was approved to establish The Key Laboratory of Human Genome Research by the Shanghai Municipal Commission of Science and Technology in 1993 and also by the Ministry of Public Health of China in 1994. In 2001, the State Key Laboratory of Medical Genomics was approved to be established in the Institute by the Ministry of Science and Technology of China. In 2013 the first National Research Center for Translational Medicine in China was approved and the SIH research teams have played a major role at the Center. After the success of the APL treatment, we are determined to make breakthroughs in a second type of leukemia with targeted therapy.

What impact has collaboration with Dr. Waxman and the grantees of the Samuel Waxman Cancer Research Foundation had on the work of the SIH?

The work of the SIH has benefited a lot from the collaboration with Dr. Waxman and from the support from the SWCRF. First, the financial support from SWCRF in the early 1990s was very valuable at that time when there was a shortage of research funds. Second, Dr. Waxman and SWCRF contributed a lot to the training of SIH researchers, several of whom, including Zhu Chen and Sai-Juan Chen, once worked at Dr. Waxman's lab as visiting scientists. It was in Dr. Waxman's lab that Sai-Juan Chen cloned the fusion gene of a new chromosomal abnormality of APL which led to the identification of a novel subset of APL. Third, the SWCRF has served as an important platform for building awareness for the work of the SIH among international colleagues. This platform has brought us more opportunities for international collaborations.


What has been your experience collaborating with Prof. Zhu Chen and Prof. Sai-Juan Chen over the years?

The success of the APL treatment owes to the efforts of generations of researchers at the SIH and is a good paradigm of teamwork. My own work is mainly focused on the clinical studies of differentiation therapy of ATRA. When Zhu Chen and Sai-Juan Chen returned to China after their Ph.D. studies in France in 1989, they began to explore the cellular and molecular mechanisms of ATRA with the new techniques they had learned. In the late 1990s, they started to explore the synergistic effect between ATRA and arsenic trioxide in treating APL. Together, we designed the treatment protocol using the two drugs.

The SWCRF is committed to finding new therapies for cancer patients by studying the genetic and environmental causal factors of cancer in people as they age. Where do you foresee potential breakthrough findings in this category of scientific investigation?

I believe more important breakthroughs will be made in cancer research in the coming years and a deeper understanding of the dynamic of aging in cancer is an area of great potential for progress. However, I must say that there is still a long way to go for cancer treatment.

MAKING GLOBAL IMPACT



The Samuel Waxman Cancer Research Foundation's philosophy of collaboration continues to have impact around the world. SWCRF grantees Shai Izraeli, M.D., Sheba Medical Center at Tel Aviv University, and Sai-Juan Chen, M.D., Ph.D., the Shanghai Institute of Hematology, made significant progress in their international collaboration on acute leukemia research launched in 2014 after winning a grant funded by the Chinese and Israeli governments.

In 2016, the Chinese group published a groundbreaking paper describing novel types of acute lymphoblastic leukemias in adolescents and young adults in the scientific journal *EBioMedicine*. Dr. Izraeli wrote the editorial on that research in the same journal. In May 2017 the Israeli and Chinese groups published a paper in the prestigious journal *Proceedings of the National Academy of Sciences*. This research discovers, for the first time, that an oncogenic signaling pathway in childhood blood cancer may also be their "Achilles' Heel." This research has wide scientific and therapeutic implications. Additional collaborative research between Dr. Chen's team and Dr. Izraeli's team is ongoing.

Thus introductions made by SWCRF founder & CEO Samuel Waxman, M.D have promoted medical research collaborations between Israel and China, enhancing possibilities for additional partnerships between China and Israel in the field of biomedicine.



1997

SWCRF and SIH introduce first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide, which increases the disease's five-year survival rate from 25 percent to 95 percent and is now a standard treatment worldwide.

2004

The Tenth Annual Conference on Differentiation Therapy of Cancer is presented by the SWCRF and Shanghai Second Medical University in Shanghai.



THE SWCRF INTRODUCES THE VINCE CAMUTO MEMORIAL CANCER RESEARCH PROGRAM

The Samuel Waxman Cancer Research Foundation's longtime connection to the fashion industry deepened further on November 10 when Dr. Samuel Waxman announced the establishment of the SWCRF Vince Camuto Memorial Cancer Research Program at the 19th annual Collaborating for a Cure Gala. Louise Camuto, Chief Creative Officer of Camuto Group, accepted the honor in memory of her husband, who passed away of prostate cancer in 2015.

The SWCRF Vince Camuto Memorial Cancer Research Program will support epigenetic research conducted collaboratively by scientists at several leading cancer research institutes to investigate the causal role of genetic and environmental factors in the rising incidence of cancer among people as they age. The U.S. Census Bureau estimates that the population of people over 65 will reach 83.7 million in 2050, almost double its 2012 population of 43.1 million. Americans diagnosed with the most prevalent cancer types are, on average, over the age of 50. As this population booms, so will the burden of cancer.

A pioneer of the 20th century footwear industry and co-founder of Nine West, Vince Camuto is credited with revolutionizing America's affordable fashion footwear market. In 2001, Vince founded Camuto Group as a retail resource for the design, development and distribution of women's fashion footwear. Over the next 14 years he grew the company, acquired licenses and partners, introduced brands and built Camuto Group into a global business.

Vince was an avid philanthropist, with special interest in charities that benefit women, children and families.

THANK YOU

The following donors have shared The Samuel Waxman Cancer Research Foundation's vision and belief in collaboration by generously funding the Foundation's Institute Without Walls in 2016.

\$200,000+

Mr. and Mrs. Reuben Mark

\$100,000-\$199,999

Louise Camuto and the Vince Camuto Charitable Trust

Mr. and Mrs. Michael B. Nierenberg

\$50,000-\$99,999

The Rose M. Badgley Charitable Trust

Mr. and Mrs. Arminio Fraga

The Max, Malie, Dr. Leonard and Bernice Laub Foundation

Mr. and Mrs. Ira Rennert

Ms. Dena K. Weiner and Mr. David Rozenholz

Ms. Mary Henry and Mr. Howard Rubin

Steven Madden, Ltd.

\$20,000-\$49,999

Mr. and Mrs. Joseph Ades

Alston & Bird

Jack and Florence Berlin Foundation

Mr. Brian Carosielli

Dale and Peter Claman

Clear Capital

Mr. Rick Davidson

Laura and James DeMare

Dentons

EverBank

EY

Mr. and Mrs. Kenneth Fishel

Good Hill Partners

Grandstand Sports and Memorabilia, Inc.

Hunton & Williams LLP

Jefferies LLC

KPMG Foundation

Mrs. Doralise Lama

The Tammy and Jay Levine Foundation, Inc.

Mr. and Mrs. Thomas Marano

Musa and Tom Mayer

Mr. Brian McGrath

MFA Financial Inc.

Mission Global, LLC.

Mr. Martin Migliara

Morgan Stanley

Mr. and Mrs. Randal A. Nardone

Opus Capital Market Consultants, LLC

Mara and Baron Silverstein

Skadden Arps Slate Meagher & Flom

Mr. and Mrs. Joseph G. Steffa, Jr.

Syros Pharmaceuticals, Inc.

Mr. and Mrs. Laurence Tarica

Mr. and Mrs. Marc D. Taub

Three Strohm Sisters Family Foundation

Mr. and Mrs. Jeffrey Verschleiser

Bettina and Spencer Waxman

Weil, Gotshal & Manges, LLP

Mr. and Mrs. Matthew Zisette

\$10,000-\$19,999

AmTrust Title

Mr. Duane Andrews

Angelo, Gordon & Co.

Mr. and Mrs. John D. Brewer, Jr.

Mr. and Mrs. Christopher M. Callahan

Cantor Fitzgerald Relief Fund Administration

Mr. and Mrs. Peter Cherasia

Citi Business Services

Credit Suisse

Douglas Elliman Real Estate

Mr. and Mrs. Wesley Edens

Mr. and Mrs. Robert Eichler

Ms. Karen X. Fang

Jeff and Lisa Hagler

Haymakers for Hope Inc.

Hudson Bay Company

Mr. and Mrs. Marshall Inley

Mr. and Mrs. Gary Jacob

JLR Long Island, LLC

Mr. Bernard Kaminsky

Mr. and Mrs. Howard Kurz

Lafayette 148 New York

Mr. John Patrick Leo

The Litwin Foundation

M&T Bank

Mildred & Abner Levine Family Foundation

Nomura Securities International, Inc.

Mr. Thomas L. O'Grady

Mr. and Mrs. Craig Overlander

Mr. Randy Reiff

Longhill Charitable Foundation, Inc.

Susan & Elihu Rose Foundation, Inc.

Mr. Joel R. Rotondo

Lewis and Wendy Rubin

Sequential Group

Sidley Austin LLP

The Alan B. Slifka Foundation

Mr. Sheldon Solow

Mr. Charles Sorrentino

The Surf Lodge

The Tadashi Foundation

Urban Expositions

Mr. and Mrs. Joshua B. Weintraub

\$5,000-\$9,999

Access Securities

Ms. Christine Arlotta and Mr. Mario Pecoraro

Mr. and Mrs. William Arnold

Barclays North America

Bernstein Capital

Capital Craftsman

Capital One

Champagne Taittinger

Digital Risk

Dr. Robert C. and Tina Sohn Foundation

Mr. and Mrs. Robert Fishbein

The G & A Foundation

The Damon Giglio Foundation

Dr. Roger Gilbert

Green Marbles

Alyssa and Cliff Greenberg

GreenbergTraurig

Heritage Strategies LLC

Mr. and Mrs. Dennis A. Herman

Mr. and Mrs. Gershon Kekst

JP Morgan

JP Morgan Real Estate Banking

Mr. and Mrs. Edward Kaminsky

Nancy Loving & David Hinkelman

Macys

Mr. Matthew McQueen

Dr. David M. Milch Family Foundation

Morgan, Lewis & Bockius LLP

People's United Bank

Mr. George J. Petrow

Mrs. Leah P. Sanzari

Schwartz & Company, LLP

Ms. Bernice Schwartz

Gil and Debbie Schwartzberg Family Trust

Mr. Nicholas Seminara

Mr. and Mrs. Howard Shlafmitz

Mr. and Mrs. Andrew Sloves

Mr. and Mrs. Michael Smith

Mr. Nicholas P. Smith

Mr. and Mrs. Martin St. Pierre

Ms. Mary Stone and Mr. Channing Creecy

Mr. Grant Thornton

Mr. and Mrs. Mark Werner

William H. Prusoff Foundation

Norman and Rosita Winston Foundation

Mr. and Mrs. Mitchell Winter

York Restoration Corporation

\$1,000-\$4,999

Anonymous

Mrs. Karen Amster-Young and Mr. Benjamin Young

Mr. Zach Aronson

Ashley Carespodi

Ms. Marjorie Baldinger

Barneys

Mr. Jonathan Barrow

BBVA Compass

Mr. Solomon Berkoff

Mr. Stephen Bernstein

Mr. Alexandre Bettamio

Ms. LeeAnn Black

Bloomingdales

BNY Mellon Wealth Management
 Mr. and Mrs. Frederick Boos
 Borah, Goldstein, Altschuler, Nahins & Goidel, P.C.
 Mr. Tom Boran
 Ms. Sheri Bronstein
 Mr. Eric Brophy
 BTIG, LLC
 Bonnie and David Cantor
 Capital One Wealth and Asset Management
 CBS
 Mr. and Mrs. Matthew R. Chasin
 Chestnut Investors LLC
 Dr. Jean M. Chin and Dr. Stanford N. Sullum
 Ms. Jisook Choi
 CIRECA Theranostics, LLC
 Citi Private Bank
 Robin and Mitchell Cohen
 Mrs. Marilyn Cohn
 Collection 18
 Ms. Wynne Comer
 Communities Foundation of Texas
 Chris Connelly
 Converse
 The Corcoran Group, Inc.
 CRC Insurance Services, Inc
 Mr. and Mrs. Richard J. Crescenzo
 Mr. Peter Davidson
 Kwaw De Graft-Johnson
 Mr. Alexander DelCielo
 Ms. Ellen L. Diamond
 Mr. David Dietche
 Discovery Communications
 Dr. and Mrs. Ethan Dmitrovsky
 Mr. Thomas J. Doherty
 Mr. Patrick Downes
 Mr. and Mrs. John Draghi
 Mr. Ryan Driscoll
 Dr. Susan D. Drossman and Mr. Adam Sokoloff
 Mr. Thomas Durkin
 The Durnan Group
 Mr. and Mrs. Jim Egan
 Mr. and Mrs. Richard A. Eimbinder
 Elton John AIDS Foundation
 Mr. Daniel Ezra
 Mr. Timothy P. Fallon
 Vandad Fartaj
 Stefanie and Paul Feidelson
 Hilary and Joseph Feshbach
 Mr. and Mrs. Jack Feuer
 Mr. Jim Finkel
 Food Network
 Mr. and Mrs. James E. Frankel
 Mr. Gregory Freiberg
 Staci and Andrew Friedwald
 Ms. Carol Fuller Venezia
 Mr. W. Tyler Garrow
 Mr. Kevin Gately
 GBG USA Inc.
 Mr. and Mrs. Gary Gladstein
 Ms. Cheryl L. Glory
 Mr. and Mrs. Alan J. Goldberger
 Laurie and Jeff Goldberger
 Goldberg-Nash Family Foundation
 Ms. Cristain Goodhart
 Ms. Elizabeth Gordon
 Mr. and Mrs. William Gorin
 Mr. Jeff Gravelle
 Mr. Robert M. Grillo
 Mr. Jeff Gropper
 Ms. Felicia Grumet and Mr. Mitchell Levine
 Ms. Mary P. Haggerty
 Mr. and Mrs. Robert Hecht
 Mr. and Mrs. Patrick Higgins
 High Five Foundation
 Mr. Tom Hiner
 Mr. Chris Hoeffel
 Mr. Michael Hokin
 Samuel and Hannah Holzman Trust
 Howard L. Zimmerman Architects, PC
 Hudson's Bay Company
 Hunter Ambulette Ambulance Inc.
 Island Capital Group
 Mr. and Mrs. Stuart Israel
 Mr. and Mrs. Janovic
 Mr. William Joel
 Mr. Christopher Jonas
 Ms. Katherine Jones
 Mr. and Mrs. Kenneth Joseph
 Mr. Brian F. Kane
 Ms. Mary Y. Kantor
 Mr. Robert Kantor
 Ms. Shannon Karches
 Mr. Howard Kaskel
 Deena and Erik Katz
 Ms. Tracey Keegan
 Sanjeev Khanna
 Mr. and Mrs. David J. Klein
 Kleinberg, Kaplan, Wolff & Cohen, PC
 Mr. and Mrs. Norman Kramer
 Mr. and Mrs. Eric L. Kriftcher
 Mr. and Mrs. Michael Labadorf
 Mr. Andre Lacouture
 Ariel Lahmi
 Darrin R. Lang
 Mr. Carey F. Lathrop
 Mr. William Lauder
 Mr. and Mrs. Robert Lawrence
 Dr. and Mrs. Albert M. Lefkovits
 Mr. Lawrence J. Levine
 Stephanie and Larry Levy
 Mr. Alexander Libin
 Dr. and Mrs. Jonathan D. Licht
 Ms. Maribel Lieberman
 Lift Strategic Partners
 Janet and Avery Lipman
 Mr. and Mrs. George A. Livingston
 M&E 416 E 13th St., LLC
 The M & T Charitable Foundation
 Mr. Charles Macintosh
 The David & Sandra Mack Foundation, Inc.
 Mr. Denis Manelski
 Ms. Charu Mani
 Mr. and Mrs. Jeffrey Mann
 Mr. John Mann
 Mr. and Mrs. Satish M. Mansukhani
 Marcus & Pollack LLP
 Marcus & Associates, LLC
 Mariner Investment Group, Inc.
 Ms. Elizabeth D. Martin
 Mr. Ronald D. Mass
 Mastercard
 Max B. Cohn Family Foundation
 Maxim Capital Funding, LLC
 Mr. and Mrs. Charles McGuffog
 Mr. Craig M. Meltzer
 Mr. James W. Milton
 Ms. Pamela Morgan and Mr. Michael Trokel
 Mr. and Mrs. Bob Munsey
 Ms. Jacqueline Murphy
 Mr. David Nierenberg
 Mr. and Mrs. Ira Nierenberg
 Mr. and Mrs. Steven E. North
 Northern Trust
 Mr. John O'Keefe
 Ms. Lori Okun
 Mr. and Mrs. Daniel J. Ordan
 Orrick, Herrington & Sutcliffe LLP
 Ms. Lauren Osborne
 Partners Healthcare
 Mr. Allan L. Pashcow
 Mr. and Mrs. Arnold S. Penner
 Pere360, LLC
 Mr. and Mrs. Michael Petteruti
 Mr. and Mrs. Steve Powers
 Jamie and Mark Pollack
 Pro Teck Valuation Services
 Pyro Communications, LLC
 Mr. Perry Rahbar
 Ms. Rhonda Ramparas
 Mr. David Reedy
 Ms. Milena Resca
 Revolution Golf
 Mr. and Mrs. Bob Roberts
 Mr. Michael Romanelli
 Ms. Christina Rose
 Ms. Anita S. Rosenbloom
 Ms. Sheila Rosenblum
 Mr. & Mrs. Louis Rosenfeld
 Dr. and Mrs. Hank Ross
 Mr. and Mrs. Robert Rotanz
 Alice and Michael Rudell
 Ms. Ruthanne Ruzika
 Mr. and Mrs. John Ryding
 Mr. Sherif Sakir
 Mr. and Mrs. Charles Schaffran
 Mrs. Edwin C. Scheurer
 Mr. Allan S. Sexter
 Mr. and Mrs. Martin Shafiroff
 Eytan Shapiro
 Mr. Michael Sherman
 Mr. and Mrs. Tony M. Shogren
 Mr. Justin Short
 Mr. and Mrs. Allen Siegel
 Mr. Stephen B. Siegel
 Ms. Marcy Simon
 Mr. and Mrs. Walter Small
 Ms. Joan Solotar
 Mr. David Spector
 The Marc & Diane Spilker Foundation
 Ms. Alexandra Stanton
 Ms. Estera L. Stawski
 Stawski Partners
 Mr. Joseph G. Steffa, Sr.
 Ms. Diane Steiner

Tadashi Shoji & Associates, Inc.
 Mrs. Linda Taub
 Ms. Alex Taylor
 The Twyman Family Fund
 Tolis Advisors LP
 TouchPOS Solutions, LLC
 Mr. and Mrs. David J. Trepanier
 Warburg Realty
 VCS Group, LLC
 Dr. and Mrs. Samuel Waxman
 Mr. and Mrs. Stephen Weinstein
 Wells Fargo
 Mr. Howard Wewig
 Mr. and Mrs. Paul Whitman
 Mr. and Mrs. James Wieder
 Richard and Debra Wilpon
 Dr. and Mrs. Richard A. Wolff
 The Janet Yaseen Foundation
 Brooke and Dan Zarkowsky
 Mr. Michael A. Zimmerman

\$500-\$999

AFAR
 Ms. Kathy L. Anderson
 Anikstein Family Foundation
 Anonymous
 Judith and Alan Appelbaum
 Moris and Lana Bakhsh
 Tanya and Barry Barnett
 Mr. Robert H. Beinfeld
 Mr. Harvey Bernstein
 Zoe Bernstein
 Mr. Dwight Bostic
 Mr. John Brady
 Mr. Scott A. Carlson
 The Charatan/Holm Family Foundation, Inc.
 Mr. and Mrs. Lee Charles
 Ms. Claudine Cher-Young
 Mr. and Mrs. Ralph Cioffi
 Mr. and Mrs. Harold K. Cohen
 Paula and Richard Cohen
 Mr. Ken Coopersmith
 D' Angelico Guitars
 Ms. Rosalind Devon and Mr. Sanford Batkin
 Diray Media
 E.W. Gordon & Company, Inc.
 Epic Elevator
 Mr. and Mrs. Michael Feinstein
 Mr. Richard Ferrucci
 New York Flooring Corp
 Mr. Frank J. Folz
 Mr. Thomas Geraghty
 Gilman Wealth Management at Morgan Stanley
 Mr. and Mrs. Michael Gleit
 Ms. Judith J. Gische and Mr. Steven A. Schurkman
 Mr. and Mrs. Jeffery Goldman
 Goodstein Development
 Ms. Adrienne Gordon and Mr. Gary Herman
 Mr. and Mrs. Jesse Gottlieb
 Mr. Kenneth Grossman
 Ms. Mimi Grotto
 Mr. Eric Hadley
 Amy and Bill Handwerker
 Jane and Lowen Hankin

Mr. and Mrs. Robert Harrison
 Ms. Rudene Haynes
 Mr. Kevin Higgins
 Midge and Morty Howard
 Mr. Dennis R. Hughes
 Mr. Naphtali Joseph
 Mr. and Mrs. Bill Joseph
 Freddi and Harvey Kadden
 Ms. Nurit Kahane and Mr. Werner Haase
 Mr. and Mrs. Gerald P. Kaminsky
 Team Systems Corporation
 Mr. Eric Kaplan
 Ms. Diane Katz
 Mr. and Mrs. Steven Keltz
 Mrs. Sharon Wilkes Kinberg and Mr. Robert Kinberg
 Mr. Harvey S. Knopman
 Ms. Bridget Koch
 Kranz & Co
 Kreitsek
 Mr. and Mrs. Norman Lattman
 David and Marcia Lavipour
 Ms. Jeanne Lawrence
 Bernard and Phyllis Leventhal
 Linda Iannacci, Inc.
 Ms. Erica Linden-Fineberg
 Mr. Robert Mann
 MANM Productions
 Hyman & Ruth Muss Foundation
 Mr. and Mrs. Daniel M. Nolan
 Mr. James S. Olson
 P & F Industries, Inc.
 Ms. Gabrielle Palay
 Ms. Erica D. Pearl
 Pearlgreen Corporation
 Mr. Dennis B. Poster
 Ms. Laura Pozvolksa
 Protective Lining Corporation
 Mr. and Mrs. Marc Puntas
 RMS Fashions, Inc.
 Jodi and Robert D. Rosenthal Family Foundation
 Ms. Sandy Rosenthal
 Ms. Margie Rotchford
 Roztayger, LLC
 Mr. Richard Rubenstein
 Rubie's Costume Company, Inc.
 Ms. Ali Sanders
 Mr. Anand Sankaranarayanan
 Mr. Phil Sarna
 Mr. Jeff Schecter
 Ms. Theresa Scotto
 Mr. Craig Sedmak
 Mr. Neil Simon
 Mr. David Smalstig
 Ms. Joanne B. Snider
 Mr. Greg Sobreiro
 Mr. and Mrs. Michael Sokol
 Barbara and Richard Solomon
 Mr. Jason Spieler
 Dr. Barry Sporer
 Stamford Tent
 Ms. Candice Stark
 Ms. Claudia Taglich
 Mr. and Mrs. Jeremy Tocco

Ms. Sharon M. Tomao
 Mr. Moshe Vardi
 Mr. and Mrs. Jonathan Weber
 The Wechsler Foundation
 Dr. Paul Wein
 Norman Weisfeld
 Mr. Aaron Welsh
 Whispering Bells Foundation
 Mr. and Mrs. John Woudsma
 Zinon

IN-KIND DONORS

12mYDF
 69 Main Gallery
 AmTrust Title
 Amy Bloustine Coaching
 Analar Corporation
 Antico Noe
 Arlotta Cashmere
 Arlotta Food Studio
 Backyard Brine
 Bareburger
 Baron's Cove
 Bespoke Real Estate
 BLT Steak
 Blue and Cream
 Blue Island Oysters
 Bradford Renaissance Corp.
 Café Continental
 Canyon Ranch
 Casa Lever
 Champagne Taittinger
 Chopin Vodka
 Cipriani
 Clarkson Avenue Crumb Cake Co.
 Cloud Catering
 Columbia University
 Cushnie et Ochs
 Cynthia Rowley
 Danny Clinch
 Darrell Reid
 David Burke
 Debra Schwartzberg
 Delicatessen
 DF Mavens
 Diane James Home
 Doña Sarita
 Donna Lennard
 Dragonfly by Sue North
 DW Sweets
 East End Car & Concierge
 East Hampton Grill
 Emily Cho
 Endless Summer Event Catering
 Erica's Rugelach
 Ezra Chowaiki
 Felice
 FlowerBox Wall Gardens
 François Payard
 Fresno Restaurant
 Glam & Glo
 Google Ad Grants
 Hampton Coffee Company
 Hampton Daze Magazine

Hampton Jam Company
 Hamptons Magazine
 Hans can de Bovenkamp
 Harmonia Inc
 Henry Chalfant
 Hugo Boss
 Hurricane Grill & Wings
 il Buco Vita
 Inslee by Design
 Italian Wine Merchants
 Jackie Rogers
 Jim McLean
 Joey Kramer
 John Varvatos
 Karen Klugein
 Kathy G
 Kaufman Music Center
 La Masseria
 La Prairie
 La Prairie Spa at The Ritz-Carlton New York
 Central Park
 Lafayette 148
 LDV Hospitality
 Liqqshot
 Loews Regency
 Luckybar
 Lusardi's Restaurant
 Maidstone Club
 Malin and Goetz
 Manna Restaurant and Bar
 Maoz
 Maria Bonita Salon & Spa
 Michael George
 Milwaukee Bucks
 Minnie Rose
 Mirabell Catering
 Miriam Nierenberg Aronson
 Montauk Brewing Company
 Montauk Hard Label
 My Sister's Chef
 National Academy Museum & School
 Neta Sushi
 New York Knicks
 Nicole Miller
 Noah's
 Nounós Creamery
 Noyac Country Club
 Old Stove Pub
 Oreya
 Oscar de la Renta
 P.C. Richard & Son
 Page at 63 Main
 Palm Bay International
 Palm Restaurant at Huntting Inn
 Patrick Sikorski
 Penntara Lao
 Peter Lik
 Peter Tunney
 Plain T
 Prive By Laurent D
 Rallye Motors
 Regina Kravitz
 Roberto Cavalli
 Roger Daltrey
 Ronald J. Krowne Photography

Rowdy Hall
 Roztayger
 Saaz
 Sag Harbor Inn
 Sant Ambroeus
 Sarah Eilenberg
 Saratoga Water
 Sen Restaurant
 Serena & Lily
 Silver Spoon Specialties
 Skinfluence
 Skinnytees
 Skip Barber Racing School
 Sound Aircraft Flight Enterprises
 Souza's Events
 St. John
 Steve Eichner
 Sue North
 Susan Palmer Inc
 Sylvia Weinstock Cakes LLC
 Tabooze
 Take Two Film Academy
 Talon Air
 Tavern62
 Tesla Motors of East Hampton
 The 1770 House
 The Breakers Palm Beach
 The Independent
 The Seafood Shop
 The Sole Connection
 The Surf Lodge
 Tom Marano
 Trattoria L'Incontro
 Ubon's BBQ
 Union League Club
 Valery Joseph Salon
 Vegan Divas
 Verve Medical Cosmetics
 White's Apothecary
 Williams-Sonoma
 Worth

GIFTS WERE MADE IN HONOR OR IN MEMORY OF

Mrs. Karen Amster-Young
 Mr. Ronald Bloom
 Mr. Vince Camuto
 Ms. Jayma Cardoso
 Jean Chin, M.D.
 Mr. Lou Cochet
 Mr. Avi Concool
 Mr. Mark Fizulich
 Mr. Alan Gardener
 Mrs. Donna Geraghty
 Mr. William S. Gorin
 Ms. Florence Harrison
 Linda & Dennis Herman
 Terry Hermanson
 Mr. Gary Jacob
 Mr. Howard Kurz
 Mrs. Marcia Lavipour
 Ms. Sandra Lee
 Mr. Johnny Leonard
 Mr. Jim McLean
 Elin & Michael Nierenberg

Eli Rosenblum
 Mrs. Laurie Schaffran
 Ms. Lori Schlakman
 Ms. Linda Shapiro
 Mr. Tony Shogren
 Mr. Mayer Siegel
 Mr. and Mrs. Baron Silverstein
 Ms. Andrea Stark
 Mr. David S. Taub
 Mr. Ronald Urvater
 Mr. Nat Waxman
 Mrs. Marion & Samuel Waxman, M.D.
 Mr. Spencer Waxman
 Mr. Bobby Zarin

A NOTE TO OUR SUPPORTERS

We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. The Thank You list includes all gifts made between January 1, 2016 and December 31, 2016. Gifts mentioned exclude multiple year pledges.

We make every effort to follow the donor's preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know. If we have made a mistake, we sincerely apologize for our error and ask you to bring it to our attention. Please contact Dan Orvieto at 646-398-5260 so the record may be corrected. Thank you.

Photo credits:

40th Anniversary Awards/Scientific Symposium
 by Kristen Driscoll
 Collaborating for a Cure luncheon by Rob Rich/
 Society Allure.com
 NASDAQ by Frank Padrone
 A Hamptons Happening by Rob Rich/Society
 Allure.com
 Golf tournament by Jerry Lacay
 Lafayette 148 New York/Pay it Forward by
 Astrid Stawiarz/Getty
 Tadashi/Pay it Forward courtesy Tadashi Shoji
 Blow Out Breast Cancer by James Edstrom
 Gala by Patrick McMullan
 Cover photo by Kristen Driscoll

FINANCIAL STATEMENT

July 1, 2015 — June 30, 2016 audited

REVENUE

Contributions	\$312,000
Program Grants	906,000
Event Income	1,575,000
Investment Income	8,000

Total Revenue	\$2,801,000
----------------------	--------------------

EXPENSE

Program Services	1,752,000
Fundraising	542,000
Management and General	194,000

Total Expense	\$2,488,000
----------------------	--------------------

Surplus	\$313,000
----------------	------------------

SAMUEL WAXMAN CANCER RESEARCH FOUNDATION

FOUNDATION TEAM

Founder and Chief Executive Officer – Samuel Waxman, M.D.
Chief Scientific Officer – Jonathan Licht, M.D.
Chief Mission Officer – Alan Rosmarin, M.D.
Executive Director – William T. Sullivan
Director of Special Events – Bridget Stein
Director of Marketing and Communications – Edgar Trinidad
Development and Operations Coordinator – Rachel Kramer
Development Coordinator – Erica Linden-Fineberg
Scientific Advisory Board – Steven D. Gore, M.D., Lorraine Gudas, Ph.D., Robert Hromas, M.D., Ramon Parsons, M.D., Ph.D., Nancy Speck, Ph.D., Hua Yu, Ph.D.

FOUNDATION BOARD

Chairman – Michael Nierenberg
President – Spencer Waxman
Vice Presidents – Howard Kurz, Dena K. Weiner
Treasurer – Thomas A. Conway
Secretary – Laurie L. Schaffran
Board of Directors – Kenneth Fishel, James E. Frankel, Gary Gladstein, Clifford Greenberg, Dennis A. Herman, Linda Herman, David Hinkelman, Gary Jacob, Robert Kantor, Matthew Lyons, Riva Ariella Ritvo-Slifka, Lewis A. Rubin, Howard Shlafmitz, Baron Silverstein, David S. Taub+, Samuel Waxman, M.D.
Honorary Board – Maureen Cogan, Martin L. Coyne, Mary Kantor, Abner Levine +, Mildred Levine +, Susan W. Rose, Alan P. Safir *, Joan A. Safir *, Edwin C. Scheurer +, Alfred J. Seaman *+, Zena Wiener
Chairman's Council – Lawrence Altman, Dale Claman, Peter Claman, Ruth Finley, Arminio Fraga, Betsey Johnson, Costas Kondylis, Thomas Marano, J. Jay Mautner, Tony M. Shogren, Tadashi Shoji, Bernard Sillins

* Past Chair + Deceased

